Several studies including immunotherapeutic strategies and inhibitors of VEGFR, IGF-1R, PI3K/AKT/mTOR and MET have been conducted, being expected in a near future a shift in the management of oral cancer patients towards more personalized treatment. Here, MET is linked to lip and oral cavity carcinoma.